• Sandra Ihne, Caroline Morbach, Claudia Sommer, Andreas Geier, Stefan Knop, and Stefan Störk.
• Interdisciplinary Amyloidosis Center of Northern Bavaria, University Hospital Würzburg, Germany; Medical Clinic and Policlinic II, Dept. of Hemtatology, University Hospital Würzburg, Germany; Comprehensive Heart Failure Center Würzburg, University and University Hospital Würzburg, Germany; Medical Clinic and Policlinic I, Dept. of Cardiology, University Hospital Würzburg, Germany; Department of Neurology, University Hospital Würzburg, Germany; Medical Clinic and Policlinic II, Dept. of Hepatology, University Hospital Würzburg, Germany.
• Dtsch Arztebl Int. 2020 Mar 6; 117 (10): 159-166.

BackgroundSystemic amyloidosis is a multi-system disease caused by fibrillary protein deposition with ensuing dysfunction of the affected organ systems. Its diagnosis is often delayed because the manifestations of the disease are variable and non-specific. Its main forms are light chain (AL) amyloidosis and transthyretinrelated ATTR amyloidosis, which, in turn, has both a sporadic subtype (wildtype, ATTRwt) and a hereditary subtype (mutated, ATTRv).MethodsThis review is based on pertinent publications that were retrieved by a selective search in PubMed covering the years 2005 to 2019.ResultsNo robust epidemiological figures are available for Germany to date. Both AL amyloidosis and hereditary ATTR amyloidosis are rare diseases, but the prev - alence of ATTRwt amyloidosis is markedly underestimated. The diagnostic algorithm is complex and generally requires histological confirmation of the diagnosis. Only cardiac ATTR amyloidosis can be diagnosed non-invasively with bone scintigraphy once a monoclonal gammopathy has been excluded. AL amyloidosis can be considered a complication of a plasma cell dyscrasia and treated with reference to patterns applied in multiple myeloma. Despite the availability of causally directed treatment, it has not yet been possible to reduce the mortality of advanced cardiac AL amyloidosis. Three drugs (tafamidis, patisiran, and inotersen) are now available to treat grade 1 or 2 polyneuropathy in ATTRv amyloidosis, and further agents are now being tested in clinical trials. It is expected that tafamidis will soon be approved in Germany for the treatment of cardiac ATTR amyloidosis.ConclusionThe diagnosis of amyloidosis is difficult because of its highly varied presentation. In case of clinical suspicion, a rapid, targeted diagnostic evaluation and subsequent initiation of treatment should be performed in a specialized center. When the new drugs to treat amyloidosis become commercially available, their use and effects should be documented in nationwide registries.

10 keywords...

hide…